Clinical trials
Hematologic Diseases trials in Israel
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
20 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2008 | 1 |
| 2013 | 1 |
| 2014 | 2 |
| 2017 | 4 |
| 2018 | 1 |
| 2020 | 2 |
| 2021 | 4 |
| 2022 | 2 |
| 2023 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 12 |
| Active, not recruiting | 6 |
| Enrolling by invitation | 1 |
| Recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Loxo Oncology, Inc. | 4 |
| BioMarin Pharmaceutical | 3 |
| Bnai Zion Medical Center | 2 |
| Pfizer | 2 |
| Cellectar Biosciences, Inc. | 1 |
| European Society for Blood and Marrow Transplantation | 1 |
| Genzyme, a Sanofi Company | 1 |
| HaEmek Medical Center, Israel | 1 |
| Novartis Pharmaceuticals | 1 |
| Seagen Inc. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hematologic Diseases | 20 |
| Hemorrhagic Disorders | 6 |
| Lymphoma, Non-Hodgkin | 6 |
| Blood Coagulation Disorders | 5 |
| Blood Coagulation Disorders, Inherited | 5 |
| Coagulation Protein Disorders | 5 |
| Genetic Diseases, Inborn | 5 |
| Hemophilia A | 5 |
| Bone Marrow Diseases | 4 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 4 |
Trials
Showing 76 to 20 of 20. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.